Section Arrow
KRYS.NASDAQ
- Krystal Biotech
Quotes are at least 15-min delayed:2026/01/07 17:07 EST
After Hours
Last
 267
+20.63 (+8.37%)
Bid
267
Ask
395.21
High 269.28 
Low 242.32 
Volume 3.97K 
Regular Hours (Closed)
Last
 246.37
-3.02 (-1.21%)
Day High 
254.495 
Prev. Close
249.39 
1-M High
265.915 
Volume 
360.86K 
Bid
267
Ask
395.21
Day Low
245.675 
Open
250.45 
1-M Low
227.8601 
Market Cap 
7.23B 
Currency 美元 
P/E 37.39 
%Yield -- 
10-SMA 249.55 
20-SMA 244.34 
50-SMA 220.83 
52-W High 265.915 
52-W Low 122.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
6.67/10.21
Enterprise Value
7.24B
Balance Sheet
Book Value Per Share
39.24
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
290.52M
Operating Revenue Per Share
0.30
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1256+0.0206+19.62%-- 
After Hours 0.1287 +0.0031 +2.47%
ERASErasca5.17+1.54+42.42%-- 
After Hours 4.61 -0.56 -10.83%
RXRXRecursion Pharmaceuticals4.86+0.31+6.81%-- 
After Hours 4.81 -0.05 -1.03%
VTYXVentyx Biosciences13.73+3.68+36.62%-- 
After Hours 13.73 0 0.00%
GLUEMonte Rosa Therapeutics23.28+7.27+45.41%54.09PE
After Hours 23.41 +0.13 +0.56%
Industry overview quotes are at least 15 minutes delayed
Business Description
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.